OWE-6 Multicentre evaluation of second line therapies in primary biliary cholangitis: UK experience

Abbas, Nadir; Culver, Emma L.; Thorburn, Douglas; Halliday, Neil; Crothers, Hannah; Dyson, Jessica; Phaw, April; Aspinall, Richard; Khakoo, Salim I.; Kallis, Yiannis; Smith, Belinda; Patanwala, Imran; Mccune, Anne; Hegade, Vinod S.; Chimakurthi, Chenchu; Jones, Rebecca; Orrell, Michael; Mells, George; Jones, David G.; Hirschfield, Gideon; Trivedi, Palak

doi:10.1136/gutjnl-2021-bsg.18

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the biochemical response of new treatment options, our study indicates that it is important to consider the potential survival gain and side effects of these new drugs in relation to the target population. For instance, in real-life cohorts, OCA seems to be prescribed to those with more severe PBC-related liver disease when compared with BZF ( 24 , 25 ), perhaps because currently OCA is the only approved second-line treatment option and there were toxicity concerns with fibrates. The absolute survival gain with these treatment options should therefore be assessed separately from the biochemical response.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, not all potential long-term clinical benefits of peroxisome proliferator–activated receptor and farnesoid X receptor agonism may be captured by the reduction of the GLOBE score ( 8 ). For instance, OCA therapy led to substantial alanine aminotransferase declines (which was also more pronounced when compared with the BZF therapy) ( 25 ). Despite being relevant prognostic markers, the hepatic transaminases are not included in the GLOBE score.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Treatment of primary biliary cholangitis (PBC) can improve the GLOBE score. We aimed to assess the association between changes in the GLOBE score (DGLOBE) and liver transplantation (LT)-free survival in patients with PBC who were treated with ursodeoxycholic acid (UDCA). METHODS:Among UDCA-treated patients within the Global PBC cohort, the association between DGLOBE (DGLOBE 0-1 : during the first year of UDCA, DGLOBE 1-2 : during the second year) and the risk of LT or death was assessed through Cox regression analyses. RESULTS:Overall, 3,775 UDCA-treated patients were included; 3,424 (90.7%) were female, the median age was 54.0 (interquartile range [IQR] 45.9-62.4) years, and the median baseline GLOBE score was 0.25 (IQR 20.47 to 0.96). During a median follow-up of 7.2 (IQR 3.7-11.5) years, 730 patients reached the combined end point of LT or death. The median DGLOBE 0-1 was 20.27 (IQR 20.56 to 0.02). Cox regression analyses, adjusted for pretreatment GLOBE score and DGLOBE 0-1 2 , showed that DGLOBE was associated with LT or death (adjusted hazard ratio 2.28, 95% confidence interval 1.81-2.87, P < 0.001). The interaction between baseline GLOBE score and DGLOBE 0-1 was not statistically significant (P 5 0.296). The DGLOBE 1-2 was associated with LT or death (adjusted hazard ratio 2.19, 95% confidence interval 1.67-2.86, P < 0.001), independently from the baseline GLOBE score and the change in GLOBE score during the first year of UDCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Obeticholic Acid for Primary Biliary Cholangitis

2022

View full text Add to dashboard Cite

Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis and/or cirrhosis. Treatment options are currently limited. The first-line therapy for this disease is the drug ursodeoxycholic acid (UDCA), which has been proven to normalize serum markers of liver dysfunction, halt histologic disease progression, and lead to a prolongation of transplant-free survival. However, 30–40% of patients unfortunately do not respond to this first-line therapy. Obeticholic acid (OCA) is the only registered agent for second-line treatment in UDCA-non responders. In this review, we focus on the pharmacological features of OCA, describing its mechanism of action of and its tolerability and efficacy in PBC patients. We also highlight current perspectives on future therapies for this condition.

show abstract

OWE-6 Multicentre evaluation of second line therapies in primary biliary cholangitis: UK experience

Cited by 2 publications

References 0 publications

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis

Obeticholic Acid for Primary Biliary Cholangitis

Contact Info

Product

Resources

About